Author:
Tanashat Mohammad,Manasrah Almothana,Abouzid Mohamed
Publisher
Springer Science and Business Media LLC
Reference4 articles.
1. Tanashat M, Manasrah A, Abouzid M (2024) Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-024-03660-2
2. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77:243–255. https://doi.org/10.1016/j.jacc.2020.11.008
3. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV (2023) Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook
4. Lee MMY, Brooksbank KJM, Wetherall K et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143:516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186